<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341039</url>
  </required_header>
  <id_info>
    <org_study_id>cAVM-PHIL Registry</org_study_id>
    <nct_id>NCT03341039</nct_id>
  </id_info>
  <brief_title>PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)</brief_title>
  <official_title>PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation a European Multi-center, Observational, Prospective, Single Arm and Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinSearch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Microvention-Terumo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy and safety of PHIL® liquid
      embolic agent in endovascular embolization of cerebral arteriovenous malformations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an European multi-center observational study. Treatments and follow-up visits will be
      done as per standard of care.

      The objective of this study is to evaluate the efficacy and safety of the PHIL® device in the
      treatment of intracranial cerebral arteriovenous malformation. The PHIL® device, a
      non-adhesive liquid embolic agent, has been CE marked since July 2014. It is intended for use
      in the embolization of lesions in the peripheral and neurovasculature, including
      arteriovenous malformations and hypervascular tumors.

      All patients with a cAVM, ruptured or unruptured, eligible for endovascular treatment with a
      liquid embolic agent, PHIL®, based on multidisciplinary consensus are eligible for this
      study. A maximum of 108 patients will be enrolled in 18 European Institutions.

      The expected approximate study duration is 39 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Months</target_duration>
  <primary_outcome>
    <measure>Overall cure rate</measure>
    <time_frame>immediately after final embolization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cure rate with regard to the aim of the endovascular treatment</measure>
    <time_frame>immediately after final embolization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall cure rate</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cure rate with regard to the aim of the endovascular treatment</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome compared to baseline</measure>
    <time_frame>up to 3 days</time_frame>
    <description>Assessment by mRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome compared to baseline</measure>
    <time_frame>1 month after each embolization</time_frame>
    <description>Assessment by mRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcome compared to baseline</measure>
    <time_frame>3-6 months after the final embolization</time_frame>
    <description>Assessment by mRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 months after last embolization</time_frame>
    <description>AE related to the PHIL procedure and/or to the techniques used during each embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total volume of injected PHIL</measure>
    <time_frame>during each embolization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume/superselective injection</measure>
    <time_frame>during each embolization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of reflux of PHIL</measure>
    <time_frame>during each embolization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of pedicles catheterized</measure>
    <time_frame>during each embolization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall injection time</measure>
    <time_frame>during each embolization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall radiation dose given to the patient during EVT</measure>
    <time_frame>during each embolization</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Cerebral AV Malformation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a cAVM, ruptured or unruptured, eligible for endovascular treatment with
        a liquid embolic agent, PHIL®, based on multidisciplinary consensus.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients with a ruptured or unruptured and previously endovascularly untreated
             cAVM that are eligible for endovascular treatment with PHIL® alone or in conjunction
             with N-Butyl cyanoacrylate glue (NBCA) and/or coils (e.g. if &quot;pressure cooking&quot;
             technique is needed or used).

          2. All patients with a previously endovascularly treated cAVM in which NBCA and/or coils
             (but not another non-adhesive liquid embolic agent) have been used may be included.**

          3. All patients with a remaining cAVM, ruptured or unruptured, that has previously been
             treated with NS and/or RT may be included.

          4. Patient or patient's legally authorized representative has received information about
             data collection and has signed and dated an Informed Consent Form. (Based on the
             country's regulation).

        Exclusion Criteria:

          1. cAVM not eligible for endovascular treatment

          2. cAVM previously treated with a non-adhesive liquid embolic agent other than PHIL®

          3. Treatment requiring the use of any other non-adhesive embolic liquid

          4. Patient is allergic to iodine

          5. Premature and newborn infant

          6. Patient with renal failure or significant liver impairment

          7. Patient is participating in another study evaluating other medical devices, other
             procedures or medications.

          8. Any other condition that might prevent patient participation in the study or follow up

          9. Patient does not want to and/or refuses to give consent to the collection and
             processing of data required for centralized monitoring
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andres Gamez</last_name>
    <phone>0033661451518</phone>
    <email>andres.gamez@microvention.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Boyer</last_name>
    <phone>003367013998</phone>
    <email>patricia.boyer@microvention.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet University</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Markus Holtmannspötter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pellgrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florent Maire</last_name>
      <email>florent.maire@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Barreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Spelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine Tarnaud</last_name>
      <email>neuro-radiologie@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Charbel Mounayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Lopes</last_name>
      <email>llopes@for.paris</email>
    </contact>
    <investigator>
      <last_name>Michel Piotin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Christine Januel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario General de Catalunya</name>
      <address>
        <city>Barcelona</city>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leopoldo Guimaraens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora del Rosario</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alfredo Casasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guillermo Parrilla Reverter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Romance Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alejandro Gonzales Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhus Umea</name>
      <address>
        <city>Umeå</city>
        <zip>90746</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mats Cronqvist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ljbubisa Borota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Saleh Lamin, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Mark Keston, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lesley Honeyfield</last_name>
      <email>lesley.honeyfield@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Lyriakos Lobotesis, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

